Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Pelacarsen (TQJ230) is a potent Lp(a)-lowering agent with promising efficacy and a favorable safety profile. However, its definitive role in reducing atherosclerotic cardiovascular events remains to be established. Ongoing Phase 3 trials will be critical in determining whether its lipid-lowering effects translate into meaningful long-term cardiovascular outcomes.
Authors
- Debabrata Mukherjee (ORCID: https://orcid.org/0000-0002-5131-3694)
- Lakshmi Kattamuri
- Kunal Sharma (ORCID: https://orcid.org/0000-0001-5720-0706)
Institutions
- Texas Tech University (US)
- The University of Texas at El Paso (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- Cardiovascular & Haematological Disorders - Drug Targets
- Published
- 2025-10-14
- DOI
- https://doi.org/10.2174/011871529x399029250923100015
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00